nach oben

Erschienen in:

21.01.2021 | Educational Review

Predictors of progression in autosomal dominant and autosomal recessive polycystic kidney disease

verfasst von: Eric G. Benz, Erum A. Hartung

Erschienen in: Pediatric Nephrology | Ausgabe 9/2021

Einloggen, um Zugang zu erhalten

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD) are characterized by bilateral cystic kidney disease leading to progressive kidney function decline. These diseases also have distinct liver manifestations. The range of clinical presentation and severity of both ADPKD and ARPKD is much wider than was once recognized. Pediatric and adult nephrologists are likely to care for individuals with both diseases in their lifetimes. This article will review genetic, clinical, and imaging predictors of kidney and liver disease progression in ADPKD and ARPKD and will briefly summarize pharmacologic therapies to prevent progression.

Bergmann C, Guay-Woodford LM, Harris PC, Horie S, Peters DJM, Torres VE (2018) Polycystic kidney disease. Nat Rev Dis Prim 4:50. https://doi.org/10.1038/s41572-018-0047-yCrossRefPubMed

Roy S, Dillon MJ, Trompeter RS, Barratt TM (1997) Autosomal recessive polycystic kidney disease: long-term outcome of neonatal survivors. Pediatr Nephrol 11:302–306. https://doi.org/10.1007/s004670050281CrossRefPubMed

Bergmann C, Senderek J, Windelen E, Küpper F, Middeldorf I, Schneider F, Dornia C, Rudnik-Schöneborn S, Konrad M, Schmitt CP, Seeman T, Neuhaus TJ, Vester U, Kirfel J, Büttner R, Zerres K, Abel E, Ala-Mello S, Ausserer B, Bald M, Beetz R, Besbas N, Brandis M, Coulthard M, Dippel J, Garcia CD, Fischbach M, Foged N, Frishberg Y, Gellermann J, Gordjani N, Häffner K, Hennekam RC, Hoppe B, Hoyer P, John U, Kääriäinen H, Kemper MJ, Koivisto P, Krüger G, Kuwertz-Bröcking E, Lambert D, Lennert T, Li Volti S, Mache C, Matthijs G, Mehls O, Meiner V, Misselwitz J, Mononen T, Müller-Wiefel DE, Mustonen A, Özen S, Oliveira JP, Pirson Y, Querfeld U, Rascher W, Rudin C, Santos HG, Schröder M, Seyberth HW, Shalev S, Shohat M, Strehlau J, Vierimaa O, Völpel S, Wilson M, Zimmerhackl B (2005) Clinical consequences of PKHD1 mutations in 164 patients with autosomal-recessive polycystic kidney disease (ARPKD). Kidney Int 67:829–848. https://doi.org/10.1111/j.1523-1755.2005.00148.xCrossRefPubMed

Burgmaier K, Kilian S, Bammens B, Benzing T, Billing H, Büscher A, Galiano M, Grundmann F, Klaus G, Mekahli D, Michel-Calemard L, Milosevski-Lomic G, Ranchin B, Sauerstein K, Schaefer S, Shroff R, Sterenborg R, Verbeeck S, Weber LT, Wicher D, Wühl E, Dötsch J, Schaefer F, Liebau MC (2019) Clinical courses and complications of young adults with Autosomal Recessive Polycystic Kidney Disease (ARPKD). Sci Rep 9:7919. https://doi.org/10.1038/s41598-019-43488-wCrossRefPubMedPubMedCentral

Gunay-Aygun M, Font-Montgomery E, Lukose L, Tuchman M, Graf J, Bryant JC, Kleta R, Garcia A, Edwards H, Piwnica-Worms K, Adams D, Bernardini I, Fischer RE, Krasnewich D, Oden N, Ling A, Quezado Z, Zak C, Daryanani KT, Turkbey B, Choyke P, Guay-Woodford LM, Gahl WA (2010) Correlation of kidney function, volume and imaging findings, and PKHD1 mutations in 73 patients with autosomal recessive polycystic kidney disease. Clin J Am Soc Nephrol 5:972–984. https://doi.org/10.2215/CJN.07141009CrossRefPubMedPubMedCentral

De Rechter S, Breysem L, Mekahli D (2017) Is autosomal dominant polycystic kidney disease becoming a pediatric disorder? Front Pediatr 5:272. https://doi.org/10.3389/fped.2017.00272CrossRefPubMedPubMedCentral

Hogan MC, Abebe K, Torres VE, Chapman AB, Bae KT, Tao C, Sun H, Perrone RD, Steinman TI, Braun W, Winklhofer FT, Miskulin DC, Rahbari-Oskoui F, Brosnahan G, Masoumi A, Karpov IO, Spillane S, Flessner M, Moore CG, Schrier RW (2014) Liver involvement in early autosomal dominant polycystic kidney disease. Clin Gastroenterol Hepatol 13:155–164. https://doi.org/10.1016/j.cgh.2014.07.051CrossRefPubMedPubMedCentral

Bergmann C (2015) ARPKD and early manifestations of ADPKD: the original polycystic kidney disease and phenocopies. Pediatr Nephrol 30:15–30CrossRef

Cornec-Le Gall E, Olson RJ, Besse W, Heyer CM, Gainullin VG, Smith JM, Audrézet M-P, Hopp K, Porath B, Shi B, Baheti S, Senum SR, Arroyo J, Madsen CD, Férec C, Joly D, Jouret F, Fikri-Benbrahim O, Charasse C, Coulibaly J-M, Yu AS, Khalili K, Pei Y, Somlo S, Le Meur Y, Torres VE, Genkyst Study Group, HALT Progression of Polycystic Kidney Disease Group, Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease, Harris PC (2018) Monoallelic mutations to DNAJB11 cause atypical autosomal-dominant polycystic kidney disease. Am J Hum Genet 102:832–844. https://doi.org/10.1016/j.ajhg.2018.03.013CrossRefPubMedPubMedCentral

10.

Porath B, Gainullin VG, Cornec-Le Gall E, Dillinger EK, Heyer CM, Hopp K, Edwards ME, Madsen CD, Mauritz SR, Banks CJ, Baheti S, Reddy B, Herrero JI, Bañales JM, Hogan MC, Tasic V, Watnick TJ, Chapman AB, Vigneau C, Lavainne F, Audrézet MP, Ferec C, Le Meur Y, Torres VE, Harris PC (2016) mutations in GANAB, encoding the glucosidase IIα subunit, cause autosomal-dominant polycystic kidney and liver disease. Am J Hum Genet 98:1193–1207. https://doi.org/10.1016/j.ajhg.2016.05.004CrossRefPubMedPubMedCentral

11.

Cornec-Le Gall E, Alam A, Perrone RD (2019) Autosomal dominant polycystic kidney disease. Lancet 393:919–935. https://doi.org/10.1016/S0140-6736(18)32782-XCrossRefPubMed

12.

Cai Y, Fedeles SV, Dong K, Anyatonwu G, Onoe T, Mitobe M, Gao JD, Okuhara D, Tian X, Gallagher AR, Tang Z, Xie X, Lalioti MD, Lee AH, Ehrlich BE, Somlo S (2014) Altered trafficking and stability of polycystins underlie polycystic kidney disease. J Clin Invest 124:5129–5144. https://doi.org/10.1172/JCI67273CrossRefPubMedPubMedCentral

13.

Cornec-Le Gall E, Audrézet M-P, Chen J-M, Hourmant M, Morin M-P, Perrichot R, Charasse C, Whebe B, Renaudineau E, Jousset P, Guillodo M-P, Grall-Jezequel A, Saliou P, Férec C, Le Meur Y (2013) Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol 24:1006–1013. https://doi.org/10.1681/ASN.2012070650CrossRefPubMedPubMedCentral

14.

Kataoka H, Fukuoka H, Makabe S, Yoshida R, Teraoka A, Ushio Y, Akihisa T, Manabe S, Sato M, Mitobe M, Tsuchiya K, Nitta K, Mochizuki T (2020) Prediction of renal prognosis in patients with autosomal dominant polycystic kidney disease using PKD1/PKD2 mutations. J Clin Med 9:146. https://doi.org/10.3390/jcm9010146CrossRefPubMedCentral

15.

Bergmann C, Von Bothmer J, Bru NO, Frank V, Fehrenbach H, Hampel T, Pape L, Buske A, Jonsson J, Sarioglu N, Ferreira JC, Becker JU, Cremer R, Hoefele J, Benz MR, Weber LT, Buettner R, Zerres K, von Bothmer J, Ortiz Bruchle N, Venghaus A, Santos A (2011) Mutations in multiple PKD genes may explain early and severe polycystic kidney disease. J Am Soc Nephrol 22:2047–2056. https://doi.org/10.1681/ASN.2010101080CrossRefPubMedPubMedCentral

16.

Rossetti S, Kubly VJ, Consugar MB, Hopp K, Roy S, Horsley SW, Chauveau D, Rees L, Barratt TM, Van’t Hoff WG, Niaudet WP, Torres VE, Harris PC (2009) Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease. Kidney Int 75:848–855. https://doi.org/10.1038/ki.2008.686CrossRefPubMedPubMedCentral

17.

Audrézet MP, Corbiere C, Lebbah S, Morinière V, Broux F, Louillet F, Fischbach M, Zaloszyc A, Cloarec S, Merieau E, Baudouin V, Deschênes G, Roussey G, Maestri S, Visconti C, Boyer O, Abel C, Lahoche A, Randrianaivo H, Bessenay L, Mekahli D, Ouertani I, Decramer S, Ryckenwaert A, Le Gall EC, Salomon R, Ferec C, Heidet L (2016) Comprehensive PKD1 and PKD2 mutation analysis in prenatal autosomal dominant polycystic kidney disease. J Am Soc Nephrol 27:722–729. https://doi.org/10.1681/ASN.2014101051CrossRefPubMed

18.

Vujic M, Heyer CM, Ars E, Hopp K, Markoff A, Örndal C, Rudenhed B, Nasr SH, Torres VE, Torra R, Bogdanova N, Harris PC (2010) Incompletely penetrant PKD1 alleles mimic the renal manifestations of ARPKD. J Am Soc Nephrol 21:1097–1102. https://doi.org/10.1681/ASN.2009101070CrossRefPubMedPubMedCentral

19.

Pandita S, Maurya D, Ramachandran V, Verma J, Kohli S, Saxena R, Verma IC (2017) Vascular endothelial growth factor (VEGF) gene promoter polymorphisms and disease progression in North Indian cohort with autosomal dominant polycystic kidney disease. Int J Mol Cell Med 6:164–173PubMedPubMedCentral

20.

Reed B, Ph D, Masoumi A, Elhassan E, Mcfann K, Ph D, Cadnapaphornchai M, Maahs D, Snell-bergeon J, Ph D, Schrier RW (2011) Angiogenic growth factors correlate with disease severity in young patients with autosomal dominant polycystic kidney disease. Kidney Int 79:128–134. https://doi.org/10.1038/ki.2010.355CrossRefPubMed

21.

Persu A, Duyme M, Pirson Y, Lens XM, Messiaen T, Breuning MH, Chauveau D, Levy M, Grünfeld JP, Devuyst O (2004) Comparison between siblings and twins supports a role for modifier genes in ADPKD. Kidney Int 66:2132–2136. https://doi.org/10.1111/j.1523-1755.2004.66003.xCrossRefPubMed

22.

Nowak KL, Cadnapaphornchai MA, Chonchol MB, Schrier RW, Gitomer B (2016) Long-Term Outcomes in Patients with Very-Early Onset Autosomal Dominant Polycystic Kidney Disease. Am J Nephrol 44:171–178. https://doi.org/10.1159/000448695CrossRefPubMed

23.

Shamshirsaz A, Bekheirnia RM, Kamgar M, Johnson AM, McFann K, Cadnapaphornchai M, Haghighi NN, Schrier RW (2005) Autosomal-dominant polycystic kidney disease in infancy and childhood: progression and outcome. Kidney Int 68:2218–2224. https://doi.org/10.1111/j.1523-1755.2005.00678.xCrossRefPubMed

24.

Mekahli D, Woolf AS, Bockenhauer D (2010) Similar renal outcomes in children with ADPKD diagnosed by screening or presenting with symptoms. Pediatr Nephrol 25:2275–2282. https://doi.org/10.1007/s00467-010-1617-8CrossRefPubMed

25.

Wong H, Vivian L, Weiler G, Filler G (2004) Patients with autosomal dominant polycystic kidney disease hyperfiltrate early in their disease. Am J Kidney Dis 43:624–628CrossRef

26.

Helal I, Reed B, McFann K, Yan X-D, Fick-Brosnahan GM, Cadnapaphornchai M, Schrier RW (2011) Glomerular hyperfiltration and renal progression in children with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 6:2439–2443. https://doi.org/10.2215/CJN.01010211CrossRefPubMedPubMedCentral

27.

Schrier RW (2009) Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 20:1888–1893CrossRef

28.

Selistre L, De Souza V, Ranchin B, Hadj-Aissa A, Cochat P, Dubourg L (2012) Early renal abnormalities in children with postnatally diagnosed autosomal dominant polycystic kidney disease. Pediatr Nephrol 27:1589–1593. https://doi.org/10.1007/s00467-012-2192-yCrossRefPubMed

29.

Seeman T, Dušek J, Vondrák K, Bláhová K, Šimková E, Kreisinger J, Dvořák P, Kynčl M, Hříbal Z, Janda J (2004) Renal concentrating capacity is linked to blood pressure in children with autosomal dominant polycystic kidney disease. Physiol Res 53:629–634PubMed

30.

Gabow PA, Johnson AM, Kaehny WD, Kimberling WJ, Lezotte DC, Duley IT, Jones RH (1992) Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int 41:1311–1319. https://doi.org/10.1038/ki.1992.195CrossRefPubMed

31.

Cornec-Le Gall E, Audrézet M-P, Rousseau A, Hourmant M, Renaudineau E, Charasse C, Morin M-P, Moal M-C, Dantal J, Wehbe B, Perrichot R, Frouget T, Vigneau C, Potier J, Jousset P, Guillodo M-P, Siohan P, Terki N, Sawadogo T, Legrand D, Menoyo-Calonge V, Benarbia S, Besnier D, Longuet H, Férec C, Le Meur Y (2016) The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 27:942–951. https://doi.org/10.1681/ASN.2015010016CrossRefPubMed

32.

Sharp C, Johnson A, Gabow P (1998) Factors relating to urinary protein excretion in children with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 9:1908–1914CrossRef

33.

Chapman AB, Johnson AM, Gabow PA, Schrier RW (1994) Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 5:1349–1354CrossRef

34.

Cadnapaphornchai MA, McFann K, Strain JD, Masoumi A, Schrier RW (2009) Prospective change in renal volume and function in children with ADPKD. Clin J Am Soc Nephrol 4:820–829. https://doi.org/10.2215/CJN.02810608CrossRefPubMedPubMedCentral

35.

Gimpel C, Bergmann C, Bockenhauer D, Breysem L, Cadnapaphornchai MA, Cetiner M, Dudley J, Emma F, Konrad M, Harris T, Harris PC, König J, Liebau MC, Marlais M, Mekahli D, Metcalfe AM, Oh J, Perrone RD, Sinha MD, Titieni A, Torra R, Weber S, Winyard PJD, Schaefer F (2019) International consensus statement on the diagnosis and management of autosomal dominant polycystic kidney disease in children and young people. Nat Rev Nephrol 15:713–726. https://doi.org/10.1038/s41581-019-0155-2CrossRefPubMedPubMedCentral

36.

Dudley J, Winyard P, Marlais M, Cuthell O, Harris T, Chong J, Sayer J, Gale DP, Moore L, Turner K, Burrows S, Sandford R (2019) Clinical practice guideline monitoring children and young people with, or at risk of developing autosomal dominant polycystic kidney disease (ADPKD). BMC Nephrol 20:148. https://doi.org/10.1186/s12882-019-1285-2CrossRefPubMedPubMedCentral

37.

Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Bae KT, Moore CG, Chapman AB (2014) Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med 371:2255–2266. https://doi.org/10.1056/NEJMoa1402685CrossRefPubMedPubMedCentral

38.

Massella L, Mekahli D, Paripović D, Prikhodina L, Godefroid N, Niemirska A, Ağbaş A, Kalicka K, Jankauskiene A, Mizerska-Wasiak M, Afonso AC, Salomon R, Deschênes G, Ariceta G, Özçakar ZB, Teixeira A, Duzova A, Harambat J, Seeman T, Hrčková G, Lungu AC, Papizh S, Peco-Antic A, De Rechter S, Giordano U, Kirchner M, Lutz T, Schaefer F, Devuyst O, Wühl E, Emma F (2018) Prevalence of hypertension in children with early-stage ADPKD. Clin J Am Soc Nephrol 13:CJN.11401017. https://doi.org/10.2215/CJN.11401017CrossRef

39.

Gabow PA, Chapman AB, Johnson AM, Tangel TJ, Duley IT, Kaehny WD, Manco-Johnson M, Schrier RW (1990) Renal structure and hypertension in autosomal dominant polycystic kidney disease. Kidney Int 38:1177–1180. https://doi.org/10.1038/ki.1990.330CrossRefPubMed

40.

van Dijk MA, Breuning MH, Duiser R, van Es LA, Westendorp RGJ (2003) No effect of enalapril on progression in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 18:2314–2320. https://doi.org/10.1093/ndt/gfg417CrossRefPubMed

41.

Ecder T, Edelstein CL, Fick-Brosnahan GM, Johnson AM, Chapman AB, Gabow PA, Schrier RW (2001) Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease. Am J Nephrol 21:98–103. https://doi.org/10.1159/000046231CrossRefPubMed

42.

Jafar TH, Stark PC, Schmid CH, Strandgaard S, Kamper AL, Maschio G, Becicer G, Perrone RD, Levey AS (2005) The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease. Kidney Int 67:265–271. https://doi.org/10.1111/j.1523-1755.2005.00077.xCrossRefPubMed

43.

Nutahara K, Higashihara E, Horie S, Kamura K, Tsuchiya K, Mochizuki T, Hosoya T, Nakayama T, Yamamoto N, Higaki Y, Shimizu T (2005) Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease. Nephron Clin Pract 99:18–23. https://doi.org/10.1159/000081790CrossRef

44.

Andries A, Daenen K, Jouret F, Bammens B, Mekahli D, Van Schepdael A (2019) Oxidative stress in autosomal dominant polycystic kidney disease: player and/or early predictor for disease progression? Pediatr Nephrol 34:993–1008CrossRef

45.

Nowak KL, Wang W, Farmer-Bailey H, Gitomer B, Malaczewski M, Klawitter J, Jovanovich A, Chonchol M (2018) Vascular dysfunction, oxidative stress, and inflammation in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 13:1493–1501. https://doi.org/10.2215/CJN.05850518CrossRefPubMedPubMedCentral

46.

Torres VE, Grantham JJ, Chapman AB, Mrug M, Bae KT, King BF, Wetzel LH, Martin D, Lockhart ME, Bennett WM, Moxey-Mims M, Abebe KZ, Lin Y, Bost JE (2011) Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 6:640–647. https://doi.org/10.2215/CJN.03250410CrossRefPubMedPubMedCentral

47.

Harris PC, Bae KT, Rossetti S, Torres VE, Grantham JJ, Chapman AB, Guay-Woodford LM, King BF, Wetzel LH, Baumgarten DA, Kenney PJ, Consugar M, Klahr S, Bennett WM, Meyers CM, Zhang Q, Thompson PA, Zhu F, Miller JP (2006) Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 17:3013–3019. https://doi.org/10.1681/ASN.2006080835CrossRefPubMed

48.

Chapman AB, Bost JE, Torres VE, Guay-Woodford L, Bae KT, Landsittel D, Li J, King BF, Martin D, Wetzel LH, Lockhart ME, Harris PC, Moxey-Mims M, Flessner M, Bennett WM, Grantham JJ (2012) Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 7:479–486. https://doi.org/10.2215/CJN.09500911CrossRefPubMedPubMedCentral

49.

Cadnapaphornchai MA, Masoumi A, Strain JD, McFann K, Schrier RW (2011) Magnetic resonance imaging of kidney and cyst volume in children with ADPKD. Clin J Am Soc Nephrol 6:369–376. https://doi.org/10.2215/CJN.03780410CrossRefPubMedPubMedCentral

50.

Yu ASL, Shen C, Landsittel DP, Harris PC, Torres VE, Mrug M, Bae KT, Grantham JJ, Rahbari-Oskoui FF, Flessner MF, Bennett WM, Chapman AB, Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) (2018) Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease. Kidney Int 93:691–699. https://doi.org/10.1016/j.kint.2017.09.027CrossRefPubMed

51.

O’Neill WC, Robbin ML, Bae KT, Grantham JJ, Chapman AB, Guay-Woodford LM, Torres VE, King BF, Wetzel LH, Thompson PA, Miller JP (2005) Sonographic assessment of the severity and progression of autosomal dominant polycystic kidney disease: the Consortium of Renal Imaging Studies in Polycystic Kidney Disease (CRISP). Am J Kidney Dis 46:1058–1064. https://doi.org/10.1053/j.ajkd.2005.08.026CrossRefPubMed

52.

Chapman AB, Guay-Woodford LM, Grantham JJ, Torres VE, Bae KT, Baumgarten DA, Kenney PJ, King BF, Glockner JF, Wetzel LH, Brummer ME, O’Neill WC, Robbin ML, Bennett WM, Klahr S, Hirschman GH, Kimmel PL, Thompson PA, Miller JP (2003) Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int 64:1035–1045. https://doi.org/10.1046/j.1523-1755.2003.00185.xCrossRefPubMed

53.

Breysem L, De Rechter S, De Keyzer F, Smet MH, Bammens B, Van Dyck M, Hofmans M, Oyen R, Levtchenko E, Mekahli D (2018) 3DUS as an alternative to MRI for measuring renal volume in children with autosomal dominant polycystic kidney disease. Pediatr Nephrol 33:827–835. https://doi.org/10.1007/s00467-017-3862-6CrossRefPubMed

54.

Bhutani H, Smith V, Rahbari-Oskoui F, Mittal A, Grantham JJ, Torres VE, Mrug M, Bae KT, Wu Z, Ge Y, Landslittel D, Gibbs P, O’Neill WC, Chapman AB, CRISP Investigators (2015) A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease. Kidney Int 88:146–151. https://doi.org/10.1038/ki.2015.71CrossRefPubMedPubMedCentral

55.

Perrone RD, Mouksassi MS, Romero K, Czerwiec FS, Chapman AB, Gitomer BY, Torres VE, Miskulin DC, Broadbent S, Marier JF (2017) Total kidney volume is a prognostic biomarker of renal function decline and progression to end-stage renal disease in patients with autosomal dominant polycystic kidney disease. Kidney Int Rep 2:442–450. https://doi.org/10.1016/j.ekir.2017.01.003CrossRefPubMedPubMedCentral

56.

US Food and Drug Administration. Biomarker Qualification Program. https://www.fda.gov/drugs/cder-biomarker-qualification-program/list-qualified-biomarkers. Accessed 27 Apr 2020

57.

Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS (2012) Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367:2407–2418. https://doi.org/10.1056/NEJMoa1205511CrossRefPubMedPubMedCentral

58.

Hartung EA (2016) Biomarkers and surrogate endpoints in kidney disease. Pediatr Nephrol 31:381–391. https://doi.org/10.1007/s00467-015-3104-8CrossRefPubMed

59.

Kline TL, Korfiatis P, Edwards ME, Bae KT, Yu A, Chapman AB, Mrug M, Grantham JJ, Landsittel D, Bennett WM, King BF, Harris PC, Torres VE, Erickson BJ (2017) Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease. Kidney Int 92:1206–1216. https://doi.org/10.1016/j.kint.2017.03.026CrossRefPubMedPubMedCentral

60.

Torres VE, King BF, Chapman AB, Brummer ME, Bae KT, Glockner JF, Arya K, Risk D, Felmlee JP, Grantham JJ, Guay-Woodford LM, Bennett WM, Klahr S, Meyers CM, Zhang X, Thompson PA, Miller JP (2007) Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2:112–120. https://doi.org/10.2215/CJN.00910306CrossRefPubMed

61.

Hayek SS, Landsittel DP, Wei C, Zeier M, Yu ASL, Torres VE, Roth S, Pao CS, Reiser J (2019) Soluble urokinase plasminogen activator receptor and decline in kidney function in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 30:1305–1313. https://doi.org/10.1681/ASN.2018121227CrossRefPubMedPubMedCentral

62.

Shuai T, Yan P, Xiong H, Huang Q, Zhu L, Yang K, Liu J (2019) Association between soluble urokinase-type plasminogen activator receptor levels and chronic kidney disease: a systematic review and meta-analysis. Biomed Res Int 2019:6927456. https://doi.org/10.1155/2019/6927456CrossRefPubMedPubMedCentral

63.

Meijer E, Boertien WE, Nauta FL, Bakker SJL, Van Oeveren W, Rook M, Van Der Jagt EJ, Van Goor H, Peters DJM, Navis G, De Jong PE, Gansevoort RT (2010) Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis. Am J Kidney Dis 56:883–895. https://doi.org/10.1053/j.ajkd.2010.06.023CrossRefPubMed

64.

Kistler AD, Serra AL, Siwy J, Poster D, Krauer F, Torres VE, Mrug M, Grantham JJ, Bae KT, Bost JE, Mullen W, Wüthrich RP, Mischak H, Chapman AB (2013) Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study. PLoS One 8:e53016. https://doi.org/10.1371/journal.pone.0053016CrossRefPubMedPubMedCentral

65.

Zhou J, Ouyang X, Cui X, Schoeb TR, Smythies LE, Johnson MR, Guay-Woodford LM, Chapman AB, Mrug M (2010) Renal CD14 expression correlates with the progression of cystic kidney disease. Kidney Int 78:550–560. https://doi.org/10.1038/ki.2010.175CrossRefPubMedPubMedCentral

66.

Chebib FT, Perrone RD, Chapman AB, Dahl NK, Harris PC, Mrug M, Mustafa RA, Rastogi A, Watnick T, Yu ASL, Torres VE (2018) A practical guide for treatment of rapidly progressive ADPKD with tolvaptan. J Am Soc Nephrol 29:2458–2470. https://doi.org/10.1681/ASN.2018060590CrossRefPubMedPubMedCentral

67.

Irazabal MV, Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ, Sundsbak JL, Bae KT, Chapman AB, Grantham JJ, Mrug M, Hogan MC, El-Zoghby ZM, Harris PC, Erickson BJ, King BF, Torres VE (2015) Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol 26:160–172. https://doi.org/10.1681/ASN.2013101138CrossRefPubMed

68.

Imaging classification of ADPKD: a simple model for selecting patients for clinical trials. https://www.mayo.edu/research/documents/pkd-center-adpkd-classification/doc-20094754

69.

McEwan P, Bennett Wilton H, Ong ACM, Ørskov B, Sandford R, Scolari F, Cabrera MCV, Walz G, O’Reilly K, Robinson P (2018) A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model. BMC Nephrol 19:37. https://doi.org/10.1186/s12882-017-0804-2CrossRefPubMedPubMedCentral

70.

De Rechter S, Bockenhauer D, Guay-Woodford LM, Liu I, Mallett AJ, Soliman NA, Sylvestre LC, Schaefer F, Liebau MC, Mekahli D, Adamczyk P, Akinci N, Alpay H, Ardelean C, Ayasreh N, Aydin Z, Bael A, Baudouin V, Bayrakci US, Bensman A, Bialkevich H, Biebuyck A, Boyer O, Bjanid O, Bryłka A, Çalışkan S, Cambier A, Camelio A, Carbone V, Charbit M, Chiodini B, Chirita A, Çiçek N, Cerkauskiene R, Collard L, Conceiçao M, Constantinescu I, Couderc A, Crapella B, Cvetkovic M, Dima B, Diomeda F, Docx M, Dolan N, Dossier C, Drozdz D, Drube J, Dunand O, Dusan P, Eid LA, Emma F, Espino Hernandez M, Fila M, Furlano M, Gafencu M, Ghuysen MS, Giani M, Giordano M, Girisgen I, Godefroid N, Godron-Dubrasquet A, Gojkovic I, Gonzalez E, Gökçe I, Groothoff JW, Guarino S, Guffens A, Hansen P, Harambat J, Haumann S, He G, Heidet L, Helmy R, Hemery F, Hooman N, llanas B, Jankauskiene A, Janssens P, Karamaria S, Kazyra I, Koenig J, Krid S, Krug P, Kwon V, La Manna A, Leroy V, Litwin M, Lombet J, Longo G, Lungu AC, Mallawaarachchi A, Marin A, Marzuillo P, Massella L, Mastrangelo A, McCarthy H, Miklaszewska M, Moczulska A, Montini G, Morawiec-Knysak A, Morin D, Murer L, Negru I, Nobili F, Obrycki L, Otoukesh H, Özcan S, Pape L, Papizh S, Parvex P, Pawlak-Bratkowska M, Prikhodina L, Prytula A, Quinlan C, Raes A, Ranchin B, Ranguelov N, Repeckiene R, Ronit C, Salomon R, Santagelo R, Saygılı SK, Schaefer S, Schreuder M, Schurmans T, Seeman T, Segers N, Sinha M, Snauwaert E, Spasojevic B, Stabouli S, Stoica C, Stroescu R, Szczepanik E, Szczepańska M, Taranta-Janusz K, Teixeira A, Thumfart J, Tkaczyk M, Torra R, Torres D, Tram N, Utsch B, Vande Walle J, Vieux R, Vitkevic R, Wilhelm-Bals A, Wühl E, Yildirim ZY, Yüksel S, Zachwieja K (2019) ADPedKD: a global online platform on the management of children with ADPKD. Kidney Int Rep 4:1271–1284. https://doi.org/10.1016/j.ekir.2019.05.015CrossRefPubMedPubMedCentral

71.

Bae KT, Zhu F, Chapman AB, Torres VE, Grantham JJ, Guay-Woodford LM, Baumgarten DA, King BF, Wetzel LH, Kenney PJ, Brummer ME, Bennett WM, Klahr S, Meyers CM, Zhang X, Thompson PA, Miller JP (2006) Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol 1:64–69. https://doi.org/10.2215/CJN.00080605CrossRefPubMed

72.

Gabow PA, Johnson AM, Kaehny WD, Manco-Johnson ML, Duley IT, Everson GT (1990) Risk factors for the development of hepatic cysts in autosomal dominant polycystic kidney disease. Hepatology 11:1033–1037. https://doi.org/10.1002/hep.1840110619CrossRefPubMed

73.

Chebib FT, Jung Y, Heyer CM, Irazabal MV, Hogan MC, Harris PC, Torres VE, El-Zoghby ZM (2016) Effect of genotype on the severity and volume progression of polycystic liver disease in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 31:952–960. https://doi.org/10.1093/ndt/gfw008CrossRefPubMedPubMedCentral

74.

Yamaguchi T, Hempson SJ, Reif GA, Hedge A-M, Wallace DP (2006) Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells. J Am Soc Nephrol 17:178–187. https://doi.org/10.1681/ASN.2005060645CrossRefPubMed

75.

Gansevoort RT, Arici M, Benzing T, Birn H, Capasso G, Covic A, Devuyst O, Drechsler C, Eckardt KU, Emma F, Knebelmann B, Le Meur Y, Massy ZA, Ong ACM, Ortiz A, Schaefer F, Torra R, Vanholder R, Więcek A, Zoccali C, Van Biesen W (2016) Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrol Dial Transplant 31:337–348. https://doi.org/10.1093/ndt/gfv456CrossRefPubMedPubMedCentral

76.

Raina R, Chakraborty R, DeCoy ME, Kline T (2020) Autosomal-dominant polycystic kidney disease: tolvaptan use in adolescents and young adults with rapid progression. Pediatr Res. https://doi.org/10.1038/s41390-020-0942-2

77.

Schaefer F, Mekahli D, Emma F, Gilbert RD, Bockenhauer D, Cadnapaphornchai MA, Shi L, Dandurand A, Sikes K, Shoaf SE (2019) Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial. Eur J Pediatr 178:1013–1021. https://doi.org/10.1007/s00431-019-03384-xCrossRefPubMedPubMedCentral

78.

Sagar PS, Zhang J, Luciuk M, Mannix C, Wong ATY, Rangan GK (2019) Increased water intake reduces long-term renal and cardiovascular disease progression in experimental polycystic kidney disease. PLoS One 14:1–18. https://doi.org/10.1371/journal.pone.0209186CrossRef

79.

Higashihara E, Nutahara K, Tanbo M, Hara H, Miyazaki I, Kobayashi K, Nitatori T (2014) Does increased water intake prevent disease progression in autosomal dominant polycystic kidney disease? Nephrol Dial Transplant 29:1710–1719. https://doi.org/10.1093/ndt/gfu093CrossRefPubMedPubMedCentral

80.

El-Damanawi R, Lee M, Harris T, Mader LB, Bond S, Pavey H, Sandford RN, Wilkinson IB, Burrows A, Woznowski P, Ben-Shlomo Y, Karet Frankl FE, Hiemstra TF (2018) Randomised controlled trial of high versus ad libitum water intake in patients with autosomal dominant polycystic kidney disease: rationale and design of the DRINK feasibility trial. BMJ Open 8:e022859. https://doi.org/10.1136/bmjopen-2018-022859CrossRefPubMedPubMedCentral

81.

Wong ATY, Mannix C, Grantham JJ, Allman-Farinelli M, Badve SV, Boudville N, Byth K, Chan J, Coulshed S, Edwards ME, Erickson BJ, Fernando M, Foster S, Haloob I, Harris DCH, Hawley CM, Hill J, Howard K, Howell M, Jiang SH, Johnson DW, Kline TL, Kumar K, Lee VW, Lonergan M, Mai J, McCloud P, Peduto A, Rangan A, Roger SD, Sud K, Torres V, Vliayuri E, Rangan GK (2018) Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD). BMJ Open 8:e018794. https://doi.org/10.1136/bmjopen-2017-018794CrossRefPubMedPubMedCentral

82.

Griffiths J, Mills MT, Ong ACM (2020) Long-acting somatostatin analogue treatments in autosomal dominant polycystic kidney disease and polycystic liver disease: a systematic review and meta-analysis. BMJ Open 10:e032620. https://doi.org/10.1136/bmjopen-2019-032620CrossRefPubMedPubMedCentral

83.

Helal I, Reed B, Schrier RW (2012) Emergent early markers of renal progression in autosomal-dominant polycystic kidney disease patients: implications for prevention and treatment. Am J Nephrol 36:162–167. https://doi.org/10.1159/000341263CrossRefPubMed

84.

Zafar I, Tao Y, Falk S, McFann K, Schrier RW, Edelstein CL (2007) Effect of statin and angiotensin-converting enzyme inhibition on structural and hemodynamic alterations in autosomal dominant polycystic kidney disease model. Am J Physiol Ren Physiol 293:F854–F859. https://doi.org/10.1152/ajprenal.00059.2007CrossRef

85.

Palaniswamy C, Selvaraj DR, Selvaraj T, Sukhija R (2010) Mechanisms underlying pleiotropic effects of statins. Am J Ther 17:75–78CrossRef

86.

Cadnapaphornchai MA (2017) Clinical trials in pediatric autosomal dominant polycystic kidney disease. Front Pediatr 5:53. https://doi.org/10.3389/fped.2017.00053CrossRefPubMedPubMedCentral

87.

Celentano S, Capolongo G, Pollastro RM (2019) Bardoxolone: a new potential therapeutic agent in the treatment of autosomal dominant polycystic kidney disease? G Ital Nefrol 36:2019-vol5PubMed

88.

Fujiki T, Ando F, Murakami K, Isobe K, Mori T, Susa K, Nomura N, Sohara E, Rai T, Uchida S (2019) Tolvaptan activates the Nrf2/HO-1 antioxidant pathway through PERK phosphorylation. Sci Rep 9:9245. https://doi.org/10.1038/s41598-019-45539-8CrossRefPubMedPubMedCentral

89.

Seliger SL, Abebe KZ, Hallows KR, Miskulin DC, Perrone RD, Watnick T, Bae KT (2018) A randomized clinical trial of metformin to treat autosomal dominant polycystic kidney disease. Am J Nephrol 47:352–360. https://doi.org/10.1159/000488807CrossRefPubMed

90.

Cadnapaphornchai MA, George DM, McFann K, Wang W, Gitomer B, Strain JD, Schrier RW (2014) Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 9:889–896. https://doi.org/10.2215/CJN.08350813CrossRefPubMedPubMedCentral

91.

Brosnahan GM, Abebe KZ, Rahbari-Oskoui FF, Patterson CG, Bae KT, Schrier RW, Braun WE, Chapman AB, Flessner MF, Harris PC, Perrone RD, Steinman TI, Torres VE (2017) Effect of Statin therapy on the progression of autosomal dominant polycystic kidney disease. a secondary analysis of the HALT PKD trials. Curr Hypertens Rev 13:109–120. https://doi.org/10.2174/1573402113666170427142815CrossRefPubMedPubMedCentral

92.

Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N, Flask CA, Novick AC, Goldfarb DA, Kramer-Zucker A, Walz G, Piontek KB, Germino GG, Weimbs T (2006) The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A 103:5466–5471. https://doi.org/10.1073/pnas.0509694103CrossRefPubMedPubMedCentral

93.

Shillingford JM, Piontek KB, Germino GG, Weimbs T (2010) Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. J Am Soc Nephrol 21:489–497. https://doi.org/10.1681/ASN.2009040421CrossRefPubMedPubMedCentral

94.

Ruggenenti P, Gentile G, Perico N, Perna A, Barcella L, Trillini M, Cortinovis M, Ferrer Siles CP, Reyes Loaeza JA, Aparicio MC, Fasolini G, Gaspari F, Martinetti D, Carrara F, Rubis N, Prandini S, Caroli A, Sharma K, Antiga L, Remuzzi A, Remuzzi G (2016) Effect of sirolimus on disease progression in patients with autosomal dominant polycystic kidney disease and CKD stages 3b-4. Clin J Am Soc Nephrol 11:785–794. https://doi.org/10.2215/CJN.09900915CrossRefPubMedPubMedCentral

95.

Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, Rentsch KM, Spanaus KS, Senn O, Kristanto P, Scheffel H, Weishaupt D, Wüthrich RP (2010) Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 363:820–829. https://doi.org/10.1056/NEJMoa0907419CrossRefPubMed

96.

Padovano V, Podrini C, Boletta A, Caplan MJ (2018) Metabolism and mitochondria in polycystic kidney disease research and therapy. Nat Rev Nephrol 14:678–687CrossRef

97.

Rowe I, Chiaravalli M, Mannella V, Ulisse V, Quilici G, Pema M, Song XW, Xu H, Mari S, Qian F, Pei Y, Musco G, Boletta A (2013) Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. Nat Med 19:488–493. https://doi.org/10.1038/nm.3092CrossRefPubMedPubMedCentral

98.

Nowak KL, Hopp K (2020) Metabolic reprogramming in autosomal dominant polycystic kidney disease: evidence and therapeutic potential. Clin J Am Soc Nephrol 15:577–584. https://doi.org/10.2215/CJN.13291019CrossRefPubMedPubMedCentral

99.

Alzarka B, Morizono H, Bollman JW, Kim D, Guay-Woodford LM (2017) Design and implementation of the hepatorenal fibrocystic disease core center clinical database: a centralized resource for characterizing autosomal recessive polycystic kidney disease and other hepatorenal fibrocystic diseases. Front Pediatr 5:80. https://doi.org/10.3389/fped.2017.00080CrossRefPubMedPubMedCentral

100.

Lu H, Galeano MCR, Ott E, Kaeslin G, Kausalya PJ, Kramer C, Ortiz-Brüchle N, Hilger N, Metzis V, Hiersche M, Tay SY, Tunningley R, Vij S, Courtney AD, Whittle B, Wühl E, Vester U, Hartleben B, Neuber S, Frank V, Little MH, Epting D, Papathanasiou P, Perkins AC, Wright GD, Hunziker W, Gee HY, Otto EA, Zerres K, Hildebrandt F, Roy S, Wicking C, Bergmann C (2017) Mutations in DZIP1L, which encodes a ciliary-transition-zone protein, cause autosomal recessive polycystic kidney disease. Nat Genet 49:1025–1034. https://doi.org/10.1038/ng.3871CrossRefPubMedPubMedCentral

101.

Adeva M, El-Youssef M, Rossetti S, Kamath PS, Kubly V, Consugar MB, Milliner DM, King BF, Torres VE, Harris PC (2006) Clinical and molecular characterization defines a broadened spectrum of autosomal recessive polycystic kidney disease (ARPKD). Medicine (Baltimore) 85:1–21. https://doi.org/10.1097/01.md.0000200165.90373.9aCrossRef

102.

Wehrman A, Kriegermeier A, Wen J (2017) Diagnosis and management of hepatobiliary complications in autosomal recessive polycystic kidney disease. Front Pediatr 5:124. https://doi.org/10.3389/fped.2017.00124CrossRefPubMedPubMedCentral

103.

Ward CJ, Hogan MC, Rossetti S, Walker D, Sneddon T, Wang X, Kubly V, Cunningham JM, Bacallao R, Ishibashi M, Milliner DS, Torres VE, Harris PC (2002) The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat Genet 30:259–269. https://doi.org/10.1038/ng833CrossRefPubMed

104.

Bergmann C, Senderek J, Sedlacek B, Pegiazoglou I, Puglia P, Eggermann T, Rudnik-Schöneborn S, Furu L, Onuchic LF, De Baca M, Germino GG, Guay-Woodford L, Somlo S, Moser M, Büttner R, Zerres K (2003) Spectrum of mutations in the gene for autosomal recessive polycystic kidney disease (ARPKD/PKHD1). J Am Soc Nephrol 14:76–89. https://doi.org/10.1136/jmg.2005.032318CrossRefPubMed

105.

Furu L, Onuchic LF, Gharavi A, Hou X, Esquivel EL, Nagasawa Y, Bergmann C, Senderek J, Avner E, Zerres K, Germino GG, Guay-Woodford LM, Somlo S (2003) Milder presentation of recessive polycystic kidney disease requires presence of amino acid substitution mutations. J Am Soc Nephrol 14:2004–2014CrossRef

106.

Burgmaier K, Kunzmann K, Ariceta G, Bergmann C, Buescher AK, Burgmaier M, Dursun I, Duzova A, Eid L, Erger F, Feldkoetter M, Galiano M, Geßner M, Goebel H, Gokce I, Haffner D, Hooman N, Hoppe B, Jankauskiene A, Klaus G, König J, Litwin M, Massella L, Mekahli D, Melek E, Mir S, Pape L, Prikhodina L, Ranchin B, Schild R, Seeman T, Sever L, Shroff R, Soliman NA, Stabouli S, Stanczyk M, Tabel Y, Taranta-Janusz K, Testa S, Thumfart J, Topaloglu R, Weber LT, Wicher D, Wühl E, Wygoda S, Yilmaz A, Zachwieja K, Zagozdzon I, Zerres K, Ranguelov N, Godefroid N, Collard L, Lombet J, Maquet J, Schalk G, Querfeld U, Beck BB, Benzing T, Buettner R, Grundmann F, Kurschat C, Benz K, Tzschoppe A, Buchholz B, Buescher R, Häffner K, Pohl M, Gross O, Krügel J, Stock J, Patzer L, Oh J, Bernhardt W, Doyon A, Vinke T, Sander A, Henn M, Derichs U, Beetz R, Jeck N, Lange-Sperandio B, Ponsel S, Kusser F, Uetz B, Benz M, Schmidt S, Huppertz-Kessler C, Kranz B, Titieni A, Wurm D, Leichter HE, Bald M, Billing H, Nabhan MM, Lara LE, Papachristou F, Emma F, Cerkauskiene R, Azukaitis K, Wasilewska A, Balasz-Chmielewska I, Miklaszewska M, Tkaczyk M, Sikora P, Zaniew M, Niemirska A, Antoniewicz J, Lesiak J, Afonso AC, Teixeira A, Milosevski-Lomic G, Paripović D, Peco-Antic A, Papizh S, Bayazit AK, Anarat A, Soylu A, Kavukcu S, Candan C, Caliskan S, Canpolat N, Emre S, Alpay H, Akinci N, Conkar S, Poyrazoglu HM, Dusunsel R, Dötsch J, Schaefer F, Liebau MC (2018) Risk factors for early dialysis dependency in autosomal recessive polycystic kidney disease. J Pediatr 199:22–28.e6. https://doi.org/10.1016/j.jpeds.2018.03.052CrossRefPubMed

107.

Ebner K, Dafinger C, Ortiz-Bruechle N, Koerber F, Schermer B, Benzing T, Dötsch J, Zerres K, Weber LT, Beck BB, Liebau MC (2017) Challenges in establishing genotype–phenotype correlations in ARPKD: case report on a toddler with two severe PKHD1 mutations. Pediatr Nephrol 32:1269–1273. https://doi.org/10.1007/s00467-017-3648-xCrossRefPubMed

108.

Deget F, Rudnik-Schaneborn S, Zerres K (1995) Course of autosomal recessive polycystic kidney disease (ARPKD) in siblings: a clinical comparison of 20 sibships. Clin Genet 47:248–253CrossRef

109.

O’Meara CC, Hoffman M, Sweeney WE Jr, Tsaih SW, Xiao B, Jacob HJ, Avner ED, Moreno C (2012) Role of genetic modifiers in an orthologous rat model of ARPKD. Physiol Genomics 44:741–753. https://doi.org/10.1152/physiolgenomics.00187.2011CrossRefPubMedPubMedCentral

110.

Richards T, Modarage K, Dean C, McCarthy-Boxer A, Hilton H, Esapa C, Norman J, Wilson P, Goggolidou P (2019) Atmin modulates Pkhd1 expression and may mediate autosomal recessive polycystic kidney disease (ARPKD) through altered non-canonical Wnt/Planar Cell Polarity (PCP) signalling. Biochim Biophys Acta Mol basis Dis 1865:378–390. https://doi.org/10.1016/j.bbadis.2018.11.003CrossRefPubMedPubMedCentral

111.

Mrug M, Li R, Cui X, Schoeb TR, Churchill GA, Guay-Woodford LM (2005) Kinesin family member 12 is a candidate polycystic kidney disease modifier in the cpk mouse. J Am Soc Nephrol 16:905–916. https://doi.org/10.1681/ASN.2004121083CrossRefPubMed

112.

Upadhya P, Churchill G, Birkenmeier EH, Barker JE, Frankel WN (1999) Genetic modifiers of polycystic kidney disease in intersubspecific KAT2J mutants. Genomics 58:129–137. https://doi.org/10.1006/geno.1999.5830CrossRefPubMed

113.

Olson RJ, Hopp K, Wells H, Smith JM, Furtado J, Constans MM, Escobar DL, Geurts AM, Torres VE, Harris PC (2019) Synergistic genetic interactions between pkhd1 and pkd1 result in an ARPKD-like phenotype in murine models. J Am Soc Nephrol 30:2113–2127. https://doi.org/10.1681/ASN.2019020150CrossRefPubMedPubMedCentral

114.

Garcia-Gonzalez MA, Menezes LF, Piontek KB, Kaimori J, Huso DL, Watnick T, Onuchic LF, Guay-Woodford LM, Germino GG (2007) Genetic interaction studies link autosomal dominant and recessive polycystic kidney disease in a common pathway. Hum Mol Genet 16:1940–1950. https://doi.org/10.1093/hmg/ddm141CrossRefPubMed

115.

Guay-Woodford LM, Bissler JJ, Braun MC, Bockenhauer D, Cadnapaphornchai MA, Dell KM, Kerecuk L, Liebau MC, Alonso-Peclet MH, Shneider B, Emre S, Heller T, Kamath BM, Murray KF, Moise K, Eichenwald EE, Evans J, Keller RL, Wilkins-Haug L, Bergmann C, Gunay-Aygun M, Hooper SR, Hardy KK, Hartung EA, Streisand R, Perrone R, Moxey-Mims M (2014) Consensus expert recommendations for the diagnosis and management of autosomal recessive polycystic kidney disease: report of an international conference. J Pediatr 165:611–617. https://doi.org/10.1016/j.jpeds.2014.06.015CrossRefPubMedPubMedCentral

116.

Szabó T, Orosz P, Balogh E, Jávorszky E, Máttyus I, Bereczki C, Maróti Z, Kalmár T, Szabó AJ, Reusz G, Várkonyi I, Marián E, Gombos É, Orosz O, Madar L, Balla G, Kappelmayer J, Tory K, Balogh I (2018) Comprehensive genetic testing in children with a clinical diagnosis of ARPKD identifies phenocopies. Pediatr Nephrol 33:1713–1721. https://doi.org/10.1007/s00467-018-3992-5CrossRefPubMed

117.

Guay-Woodford LM, Desmond RA (2003) Autosomal recessive polycystic kidney disease: the clinical experience in North America. Pediatrics 111:1072–1080CrossRef

118.

Furth SL, Pierce C, Hui WF, White CA, Wong CS, Schaefer F, Wühl E, Abraham AG, Warady BA, Samuels J, Furth S, Atkinson M, Wilson A, Quiroga A, Massengill S, Selewski D, Ferris M, Kogon A, Kaskel F, Lande M, Schwartz G, Saland J, Norwood V, Matoo T, Hidalgo G, Srivaths P, Carlson J, Langman C, Mendley S, John E, Upadhyay K, Seo-Mayer P, Patterson L, Parekh R, Robinson L, Weinstein A, Samsonov D, Kupferman J, Misurac J, Mongia A, Kiessling S, Sanchez-Kazi C, Dart A, Fathallah S, Claes D, Mitsnefes M, Blydt-Hansen T, Warady B, Greenbaum L, Flynn J, Wong C, Salusky I, Yadin O, Dell K, Jenkins R, Pan C, Ku E, Al-Uzri A, Jenkins R, Rodig N, Wong C, Davis K, Turman M, Bartosh S, Hastings C, Nayak A, Seikaly M, Benador N, Mak R, Wood E, Jenkins R, Lerner G, Barletta GM, Anarat A, Bakkaloglu A, Ozaltin F, Peco-Antic A, Querfeld U, Gellermann J, Sallay P, Drożdż D, Bonzel KE, Wingen AM, Żurowska A, Balasz I, Trivelli A, Perfumo F, Müller-Wiefel DE, Möller K, Offner G, Enke B, Wühl E, Hadtstein C, Mehls O, Schaefer F, Emre S, Caliskan S, Mir S, Wygoda S, Hohbach-Hohenfellner K, Jeck N, Klaus G, Ardissino G, Testa S, Montini G, Charbit M, Niaudet P, Caldas-Afonso A, Fernandes-Teixeira A, Dušek J, Matteucci MC, Picca S, Mastrostefano A, Wigger M, Berg UB, Celsi G, Fischbach M, Terzic J, Fydryk J, Urasinski T, Coppo R, Peruzzi L, Arbeiter K, Jankauskiené A, Grenda R, Litwin M, Janas R, Neuhaus TJ (2018) Estimating time to ESRD in children with CKD. Am J Kidney Dis 71:783–792. https://doi.org/10.1053/j.ajkd.2017.12.011CrossRefPubMedPubMedCentral

119.

Dell KM, Matheson M, Hartung EA, Warady BA, Furth SL (2016) Kidney disease progression in autosomal recessive polycystic kidney disease. J Pediatr 171:196–201.e1. https://doi.org/10.1016/j.jpeds.2015.12.079CrossRefPubMedPubMedCentral

120.

ESCAPE Trial Group, Wühl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, Zurowska A, Testa S, Jankauskiene A, Emre S, Caldas-Afonso A, Anarat A, Niaudet P, Mir S, Bakkaloglu A, Enke B, Montini G, Wingen A-M, Sallay P, Jeck N, Berg U, Caliskan S, Wygoda S, Hohbach-Hohenfellner K, Dusek J, Urasinski T, Arbeiter K, Neuhaus T, Gellermann J, Drozdz D, Fischbach M, Möller K, Wigger M, Peruzzi L, Mehls O, Schaefer F (2009) Strict blood-pressure control and progression of renal failure in children. N Engl J Med 361:1639–1650. https://doi.org/10.1056/NEJMoa0902066CrossRef

121.

Zerres K, Rudnik-Schoneborn S, Deget F, Holtkamp U, Brodehl J, Geisert J, Scharer K (1996) Autosomal recessive polycystic kidney disease in 115 children: clinical presentation, course and influence of gender. Arbeitsgemeinschaft fur Padiatrische, Nephrologie. Acta Paediatr 85:437–445CrossRef

122.

Serai SD, Otero HJ, Calle-Toro JS, Berman JI, Darge K, Hartung EA (2019) Diffusion tensor imaging of the kidney in healthy controls and in children and young adults with autosomal recessive polycystic kidney disease. Abdom Radiol 44:1867–1872. https://doi.org/10.1007/s00261-019-01933-4CrossRef

123.

Erokwu BO, Anderson CE, Flask CA, Dell KM (2018) Quantitative magnetic resonance imaging assessments of autosomal recessive polycystic kidney disease progression and response to therapy in an animal model. Pediatr Res 83:1067–1074. https://doi.org/10.1038/pr.2018.24CrossRefPubMed

124.

MacAskill CJ, Erokwu BO, Markley M, Parsons A, Farr S, Zhang Y, Tran U, Chen Y, Anderson CE, Serai S, Hartung EA, Wessely O, Ma D, Dell KM, Flask CA (2020) Multi-parametric MRI of kidney disease progression for autosomal recessive polycystic kidney disease: mouse model and initial patient results. Pediatr Res. https://doi.org/10.1038/s41390-020-0883-9

125.

Gunay-Aygun M, Font-Montgomery E, Lukose L, Tuchman Gerstein M, Piwnica-Worms K, Choyke P, Daryanani KT, Turkbey B, Fischer R, Bernardini I, Sincan M, Zhao X, Sandler NG, Roque A, Douek DC, Graf J, Huizing M, Bryant JC, Mohan P, Gahl WA, Heller T (2013) Characteristics of congenital hepatic fibrosis in a large cohort of patients with autosomal recessive polycystic kidney disease. Gastroenterology 144:112–121.e2. https://doi.org/10.1053/j.gastro.2012.09.056CrossRefPubMed

126.

Wicher D, Jankowska I, Lipiński P, Szymańska-Rożek P, Kmiotek J, Jańczyk W, Rubik J, Chrzanowska K, Socha P (2019) Transient elastography for detection of liver fibrosis in children with autosomal recessive polycystic kidney disease. Front Pediatr 6:422. https://doi.org/10.3389/fped.2018.00422CrossRefPubMedPubMedCentral

127.

Hartung EA, Wen J, Poznick L, Furth SL, Darge K (2019) Ultrasound elastography to quantify liver disease severity in autosomal recessive polycystic kidney disease. J Pediatr. https://doi.org/10.1016/j.jpeds.2019.01.055

128.

Hartung EA, Calle-Toro JS, Lopera CM, Wen J, Carson RH, Dutt M, Howarth K, Furth SL, Darge K, Serai SD (2020) Magnetic resonance elastography to quantify liver disease severity in autosomal recessive polycystic kidney disease. Abdom Radiol. https://doi.org/10.1007/s00261-020-02694-1

129.

Goto M, Hoxha N, Osman R, Dell KM (2010) The renin-angiotensin system and hypertension in autosomal recessive polycystic kidney disease. Pediatr Nephrol 25:2449–2457. https://doi.org/10.1007/s00467-010-1621-zCrossRefPubMed

130.

Goto M, Hoxha N, Osman R, Wen J, Wells RG, Dell KM (2010) Renin-angiotensin system activation in congenital hepatic fibrosis in the PCK rat model of autosomal recessive polycystic kidney disease. J Pediatr Gastroenterol Nutr 50:639–644. https://doi.org/10.1097/MPG.0b013e3181cc80e4CrossRefPubMedPubMedCentral

131.

Yoshihara D, Kugita M, Sasaki M, Horie S, Nakanishi K, Abe T, Aukema HM, Yamaguchi T, Nagao S (2013) Telmisartan ameliorates fibrocystic liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease. PLoS One 8:e81480. https://doi.org/10.1371/journal.pone.0081480CrossRefPubMedPubMedCentral

132.

Nagao S, Nishii K, Katsuyama M, Kurahashi H, Marunouchi T, Takahashi H, Wallace DP (2006) Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol 17:2220–2227. https://doi.org/10.1681/ASN.2006030251CrossRefPubMed

133.

Wang X, Wu Y, Ward CJ, Harris PC, Torres VE (2008) Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol 19:102–108. https://doi.org/10.1681/ASN.2007060688CrossRefPubMedPubMedCentral

134.

Gattone VH, Wang X, Harris PC, Torres VE (2003) Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 9:1323–1326. https://doi.org/10.1038/nm935CrossRefPubMed

135.

Wang X, Gattone V, Harris PC, Torres VE (2005) Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol 16:846–851. https://doi.org/10.1681/ASN.2004121090CrossRefPubMed

136.

Wang X, Constans MM, Chebib FT, Torres VE, Pellegrini L (2019) Effect of a Vasopressin V2 receptor antagonist on polycystic kidney disease development in a rat model. Am J Nephrol 49:487–493. https://doi.org/10.1159/000500667CrossRefPubMed

137.

Mancinelli R, Franchitto A, Glaser S, Vetuschi A, Venter J, Sferra R, Pannarale L, Olivero F, Carpino G, Alpini G, Onori P, Gaudio E (2016) Vasopressin regulates the growth of the biliary epithelium in polycystic liver disease. Lab Investig 96:1147–1155. https://doi.org/10.1038/labinvest.2016.93CrossRefPubMed

138.

Kaimori J y, Lin CC, Outeda P, Garcia-Gonzalez MA, Menezes LF, Hartung EA, Li A, Wu G, Fujita H, Sato Y, Nakanuma Y, Yamamoto S, Ichimaru N, Takahara S, Isaka Y, Watnick T, Onuchic LF, Guay-Woodford LM, Germino GG (2017) NEDD4-family E3 ligase dysfunction due to PKHD1/Pkhd1 defects suggests a mechanistic model for ARPKD pathobiology. Sci Rep 7:7733. https://doi.org/10.1038/s41598-017-08284-4CrossRefPubMedPubMedCentral

139.

Olteanu D, Yoder BK, Liu W, Croyle MJ, Welty EA, Rosborough K, Wyss JM, Bell PD, Guay-Woodford LM, Bevensee MO, Satlin LM, Schwiebert EM (2006) Heightened epithelial Na+ channel-mediated Na+ absorption in a murine polycystic kidney disease model epithelium lacking apical monocilia. Am J Physiol Physiol 290:C952–C963. https://doi.org/10.1152/ajpcell.00339.2005CrossRef

140.

Pavlov TS, Levchenko V, Ilatovskaya DV, Palygin O, Staruschenko A (2015) Impaired epithelial Na + channel activity contributes to cystogenesis and development of autosomal recessive polycystic kidney disease in PCK rats. Pediatr Res 77:64–69. https://doi.org/10.1038/pr.2014.145CrossRefPubMed

141.

Ilatovskaya DV, Levchenko V, Pavlov TS, Isaeva E, Klemens CA, Johnson J, Liu P, Kriegel AJ, Staruschenko A (2019) Salt-deficient diet exacerbates cystogenesis in ARPKD via epithelial sodium channel (ENaC). EBioMedicine 40:663–674. https://doi.org/10.1016/j.ebiom.2019.01.006CrossRefPubMedPubMedCentral

142.

Masyuk TV, Radtke BN, Stroope AJ, Banales JM, Gradilone SA, Huang B, Masyuk AI, Hogan MC, Torres VE, Larusso NF (2013) Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases. Hepatology 58:409–421. https://doi.org/10.1002/hep.26140CrossRefPubMed

143.

Sweeney WE, Avner ED (2014) Pathophysiology of childhood polycystic kidney diseases: new insights into disease-specific therapy. Pediatr Res 75:148–157. https://doi.org/10.1038/pr.2013.191CrossRefPubMed

144.

Sweeney WE, Frost P, Avner ED (2017) Tesevatinib ameliorates progression of polycystic kidney disease in rodent models of autosomal recessive polycystic kidney disease. World J Nephrol 6:188. https://doi.org/10.5527/wjn.v6.i4.188CrossRefPubMedPubMedCentral

145.

A safety, pharmacokinetic, single ascending dose study of tesevatinib in pediatric subjects with autosomal recessive polycystic kidney disease (ARPKD). In: ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03096080

146.

Ebner K, Feldkoetter M, Ariceta G, Bergmann C, Buettner R, Doyon A, Duzova A, Goebel H, Haffner D, Hero B, Hoppe B, Illig T, Jankauskiene A, Klopp N, König J, Litwin M, Mekahli D, Ranchin B, Sander A, Testa S, Weber LT, Wicher D, Yuzbasioglu A, Zerres K, Dötsch J, Schaefer F, Liebau MC, ESCAPE Study Group; GPN Study Group (2015) Rationale, design and objectives of ARegPKD, a European ARPKD registry study. BMC Nephrol 16:22. https://doi.org/10.1186/s12882-015-0002-zCrossRefPubMedPubMedCentral

147.

Forrest CB, Margolis PA, Bailey LC, Marsolo K, Del Beccaro MA, Finkelstein JA, Milov DE, Vieland VJ, Wolf BA, Yu FB, Kahn MG (2014) PEDSnet: a national pediatric learning health system. J Am Med Inform Assoc 21:602–606. https://doi.org/10.1136/amiajnl-2014-002743CrossRefPubMedPubMedCentral

148.

Smith KA, Thompson AM, Baron DA, Broadbent ST, Lundstrom GH, Perrone RD (2019) Addressing the need for clinical trial end points in autosomal dominant polycystic kidney disease: a report from the Polycystic Kidney Disease Outcomes Consortium (PKDOC). Am J Kidney Dis 73:533–541. https://doi.org/10.1053/j.ajkd.2018.11.001CrossRefPubMed

Titel: Predictors of progression in autosomal dominant and autosomal recessive polycystic kidney disease
verfasst von: Eric G. Benz
Erum A. Hartung
Publikationsdatum: 21.01.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: Pediatric Nephrology / Ausgabe 9/2021
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-020-04869-w

Dialysis disequilibrium on CKRT: avoiding the steep slippery slope

Management Dilemma

Access to treatment for chronic kidney disease by children and adolescents in Brazil

Original Article

Abstracts of the 14 th Asian Congress of Pediatric Nephrology, Taipei, Taiwan, March 2021

Abstracts

A child with green urine after a diagnostic enema: Questions

Open Access
Clinical Quiz

Critical analysis of acute kidney injury in pediatric COVID-19 patients in the intensive care unit

Zur Zeit gratis
COVID-19
Systematic Review/Meta-analysis

Dietary intakes of children with nephrotic syndrome

Original Article

Kompaktes Leitlinien-Wissen Pädiatrie (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Pädiatrie

Wie gefährlich sind E-Zigaretten?

24.04.2025
DGP 2025
Kongressbericht

E-Zigaretten (Vaper) sind nicht harmlos – sie verführen zur parallelen Nutzung von E- und Tabakzigaretten (Dual Use) und machen das Rauchen für junge Menschen attraktiv u.a. aufgrund der vielfältigen Aromastoffe. Ein niedrigschwelliger Einstieg in die Tabakentwöhnung könnten digitale Anwendungen (DiGA) sein.

ePA für Kinder und Jugendliche: Neue KBV-Richtlinie schafft Klarheit für Arztpraxen

Pädiatrie
Nachrichten

Mit einer neuen Richtlinie will die Kassenärztliche Bundesvereinigung in Abstimmung mit dem Bundesministerium für Gesundheit Sorgen der Kolleginnen und Kollegen beim Umgang mit der Kinder-ePA ausräumen. Die Richtlinie gerät arg kurz – Pädiater und Pädiaterinnen reagieren dennoch zufrieden.

Weniger Bargeld, weniger Erstickungsnotfälle?

16.04.2025
Pädiatrische Notfallmedizin
Nachrichten

Dadurch, dass immer seltener mit Bargeld gezahlt wird, könnte die Rate an Erstickungsnotfällen bei Kindern zurückgehen. Dieser Hypothese ist ein britisches Forschungsteam in Klinikdaten aus den letzten zweieinhalb Jahrzehnten nachgegangen.

Pneumonie ausschließen: Auf das Röntgenbild ist offenbar Verlass

15.04.2025
Pädiatrische Pneumologie
Nachrichten

Das Thoraxröntgen ist gemäß Daten aus den USA eine zuverlässige Methode, um bei Kindern in der Notaufnahme rasch eine Lungenentzündung auszuschließen. Zur Vorsicht rät das Ärzteteam jedoch bei bestimmten klinischen Symptomen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Predictors of progression in autosomal dominant and autosomal recessive polycystic kidney disease

Abstract

Weitere Artikel der Ausgabe 9/2021

Dialysis disequilibrium on CKRT: avoiding the steep slippery slope

Access to treatment for chronic kidney disease by children and adolescents in Brazil

Abstracts of the 14 th Asian Congress of Pediatric Nephrology, Taipei, Taiwan, March 2021

A child with green urine after a diagnostic enema: Questions

Critical analysis of acute kidney injury in pediatric COVID-19 patients in the intensive care unit

Dietary intakes of children with nephrotic syndrome

Kompaktes Leitlinien-Wissen Pädiatrie (Link öffnet in neuem Fenster)

Neu im Fachgebiet Pädiatrie

Wie gefährlich sind E-Zigaretten?

ePA für Kinder und Jugendliche: Neue KBV-Richtlinie schafft Klarheit für Arztpraxen

Weniger Bargeld, weniger Erstickungsnotfälle?

Pneumonie ausschließen: Auf das Röntgenbild ist offenbar Verlass

Update Pädiatrie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten